Pakman Healthcare (02293.HK) Hong Kong Hot Stock Analysis

Pakman Healthcare (02293.HK) is a company in the Healthcare Industry - Medical and Medical Beauty Services sector, with a current price of HK$0.51 and a market capitalization of HK$204.46 million [0]. The core driver behind its recent rise as a Hong Kong hot stock is the ex-rights and ex-dividend event on December 3, 2025, with a cash dividend of HK$0.015 per share [1]. On the ex-rights date, the trading volume reached 984,000 shares, approximately 13 times the 3-month average volume (75,850 shares) [0], and the abnormal trading activity pushed it onto the hot list.

From the price trend perspective: Over the past 10 trading days, the stock price fell from HK$0.54 to HK$0.51, a decrease of 5.56%; on the ex-rights day, it opened at HK$0.52, dipped to a low of HK$0.50, and finally closed at HK$0.51 [0][1]. Trading volume reached 888,000 shares and 984,000 shares on December 2 and December 3 respectively, far exceeding the daily average, indicating a significant increase in market participation [0][1].

1. Dividend-driven Trading
   : The company’s TTM dividend yield stands at 7.69%, higher than the industry median of 2.27% [1], attracting income-oriented investors. On November 28, Xi Xiaozhu, the company’s Chairman and CEO, was interviewed on the financial program of Radio Television Hong Kong (RTHK) [2], which further increased market attention and laid the foundation for trading enthusiasm before the ex-rights date.

2. Divergence Between Short-term Volatility and Long-term Risks
   : Although the ex-rights event brought short-term high trading volume, attention should be paid to the pressure on the company’s fundamentals. The 2025 annual net profit decreased by 43.27% year-on-year, and revenue has declined for multiple consecutive quarters [0][1]; both the current ratio (0.92) and quick ratio (0.91) are below 1, indicating certain liquidity risks [0]. The stock price has fallen by 27.14% over the past year [0], showing that the market is cautious about the company’s long-term growth prospects.

: The high dividend yield is attractive to income-oriented investors, and the short-term increase in trading volume provides trading opportunities [1].
: Continuous financial decline and liquidity pressure may affect the company’s long-term development; the price drop on the ex-rights date is a normal phenomenon, and investors need to be alert to short-term price fluctuations [0][1].

Pakman Healthcare (02293.HK) recently became a Hong Kong hot stock due to the ex-rights and ex-dividend event, with active short-term trading. Its high dividend yield attracts income-oriented investors, but investors should carefully evaluate the investment value by combining the company’s continuously declining financial performance and liquidity risks. Regarding key price levels: the support level is HK$0.49 (52-week low), and the resistance level is HK$0.75 (52-week high); investors need to pay attention to the price performance at these levels [0].